Sodium–glucose co-transporter-2 (SGLT2) inhibitors have been demonstrated in large randomised controlled trials to slow the progression of kidney disease in adults with CKD by >30% and to reduce acute kidney injury by ≈25% [9]. This evidence concerns the gene SLC5A2 and chronic kidney disease.